Upsher-Smith Launches Dicyclomine Hydrochloride Tablets

Maple Grove, MN – March 6, 2023 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Dicyclomine Hydrochloride Tablets, USP 20 mg. This product launch is a result of Upsher-Smith’s strategic partnership with CorePharma LLC, a leader in product development and manufacturing, and demonstrates Upsher-Smith’s company-wide effort to grow its portfolio of products through strategic partnerships and product acquisitions. The dicyclomine hydrochloride tablet market had U.S. sales of approximately $33 million for the 12 months ending March 2022 according to IQVIA. Product Information Product Strength NDC # Package Size Dicyclomine HCl Tablets, USP 20 mg 0832-6052-11 100-count bottle Dicyclomine HCl Tablets, USP 20 mg 0832-6052-10 1000-count bottle For questions about ordering, please call Upsher-Smith at 1-800-654-2299. Please refer to full Prescribing Information for Dicyclomine Hydrochloride Tablets, USP here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch. About Upsher-Smith Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.

The release as fetched from its publisher. upsher-smith.com ↗